文献速递淋巴瘤血栓与止血

基于表面抗体的分层管理预防淋巴瘤患者乙型肝炎病毒再激活

Stratified management based on surface antibody for the prevention of hepatitis B virus reactivation in lymphoma patients.
PubMed 文献 · Br J Haematol · 2023-10-06

该回顾性分析纳入209例基线抗-HBs滴度≥10 iu/L且抗-HBc阳性或阴性的淋巴瘤患者,6个月抗淋巴瘤治疗后15.7%失去血清学保护,中位随访28.1个月,6个月、2年、4年HBVr累积率分别为2.9%、4.7%、6.3%。开发预测模型后,高风险组血清学保护丢失率(27.8% vs 2.2%)和HBVr累积发生率(22.0% vs 0%)均高于低风险组,建议低风险患者定期监测、高风险患者早期干预。

要点

  • 209例基线抗-HBs≥10 iu/L的淋巴瘤患者中,6个月抗淋巴瘤治疗后15.7%失去血清学保护。
  • 6个月、2年、4年HBVr累积率分别为2.9%、4.7%、6.3%,中位随访28.1个月。
  • 高风险组血清学保护丢失率27.8% vs 低风险组2.2%,HBVr累积发生率22.0% vs 0%。

核心结论

  • 伴有抗-HBs阳性(无论抗-HBc是否阳性)的淋巴瘤患者存在HBVr风险,建议低风险患者定期监测、高风险患者早期干预。

研究设计与样本

  • 回顾性分析纳入209例基线抗-HBs滴度≥10 iu/L且抗-HBc阳性或阴性的淋巴瘤患者,中位随访28.1个月。

主要发现

  • 6个月抗淋巴瘤治疗后15.7%的患者失去血清学保护。
  • 6个月、2年、4年HBVr累积率分别为2.9%、4.7%、6.3%。
  • 无干预时,单纯抗-HBs阳性患者总再激活率为2.0%,抗-HBs和抗-HBc均阳性者为10.5%。
  • 高风险组血清学保护丢失率27.8% vs 低风险组2.2%,HBVr累积发生率22.0% vs 0%。

临床怎么用

  • 作者建议对低风险患者定期监测,对高风险患者早期干预。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study aimed to investigate a stratified approach based on hepatitis B virus (HBV) surface antibody (anti-HBs) for managing HBV reactivation (HBVr) in lymphoma patients with serological protection against HBV. A retrospective analysis was conducted on 209 lymphoma patients with a baseline anti-HBs titre of ≥10 iu/L, who were either positive or negative for HBV core antibody (anti-HBc). The results revealed that 15.7% of patients lost serological protection following 6-month anti-lymphoma therapy. With a median follow-up of 28.1 months, the cumulative rates of HBVr at 6 months, 2 years and 4 years were 2.9%, 4.7% and 6.3% respectively. Without intervention, the overall rate of reactivation was 2.0% for patients with isolated anti-HBs and 10.5% for those with positive anti-HBs and anti-HBc. To identify patients at high risk of losing seroprotection and susceptible to HBVr, a predictive model was developed. The high-risk group had significantly higher rates of serological protection loss (27.8% vs. 2.2%) and cumulative incidence of HBVr (22.0% vs. 0%) compared to the low-risk group. Overall, this study highlights the risk of HBVr in lymphoma patients with positive anti-HBs, with or without positive anti-HBc, and recommends periodic monitoring for low-risk patients and early intervention for high-risk patients.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Liu H, He Z, Gui R, et al. Stratified management based on surface antibody for the prevention of hepatitis B virus reactivation in lymphoma patients. Br J Haematol. 2023. PMID: 37803485. doi:10.1111/bjh.19140

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。